Oral activity of peptide bradykinin antagonists following intragastric administration in the rat

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 6, 1997, Pages 629-632

  Whalley, Eric T ^a   Hanson, Wendy L ^a   Stewart, John M ^b   Gera, Lajos ^b  

^a Departments of New Leads Chemistry and Pharmacology   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Bradykinin antagonists; Oral activity; Rat blood pressure

Indexed keywords

B 9430; BRADYKININ ANTAGONIST; CP 0597; ICATIBANT; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; HYPOTENSION; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030722615     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-075     Document Type: Conference Paper

References (14)

1. Bundy, G.L., Pals, D.T., Lawson, J.A., Couch, S.J., Lipton, M.F., and Mauragis, M.A. 1990. Potent renin inhibitory peptides containing hydrophilic end groups. J. Med. Chem. 33: 2276-2283.
2. Burkard, M., Zuzack, J.S., Jones, S., Francis, M., Whalley, E.T., Stewart, J.M., and Gera, L. 1996. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors. Immunopharmacology, 33: 186-190.
3. Fricker, G., and Drewe, J. 1996. Current concepts in intestinal peptide absorption. J. Pept. Sci. 2: 195-211.
4. Goodfellow, V.S., Marathe, M.V., Kuhlman, K.G., Fitzpatrick, T.D., Cuadrado, D., Hanson, W., Zuzack, J.S., Ross, S.E., Wieczorek, M., Burkard, M., and Whalley, E.T. 1996. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B2 and B1 receptor antagonist activity. J. Med. Chem. 39: 1472-1484.
5. Hanson, W.L., McCullough, R.G., Selig, W.M., Wieczorek, M., Ross, S., Whalley, E.T., Stewart, J.M., and Gera, L. 1996. In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors. Immunopharmacology, 33: 191-193.
6. Hock, F.J., Wirth, A.U., Linz, W., Gerhards, H.J., Wiemer, G., Henke, S., Breipohl, G., Konig, W., Knolle, J., and Scholkens, B.A. 1991. HOE140, a new potent long acting bradykinin antagonist: in vitro studies. Br. J. Pharmacol. 102: 769-773.
7. Lembeck, F., Griesbacher, T., Eckhardt, M., Henke, S., Breipohl, G., and Knolle, J. 1991. New, long-acting, potent bradykinin antagonists. Br. J. Pharmacol. 102: 297-304.
8. Llungquist, A., Feng, D.-M., Hook, W., Shen, Z.-X., Bowers, C., and Folkers, K. 1988. Antide and related antagonists of leuteinizing hormone releasing hormone with long action and oral activity. Proc. Natl. Acad. Sci. U.S.A. 85: 8236-8240.
9. Saffran, M., Bedra, C., Kumar, G.S., and Neckers, D.C. 1988. Vasopressin: a model for the study of effects of additives on oral and rectal administration of peptide drugs. J. Pharm. Sci. 77: 33-38.
10. Samanen, J., Wilson, G., Smith, P.L., Lee, C.-P., Bondinell, T.K., Rhodes, G., and Nichols, A. 1996. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J. Pharm. Pharmacol. 48: 119-135.
11. Sawutz, D.G., Salvino, J.M., Dolle, R.E., Casiano, F., Ward, S.J., Houck, W.T., Faunce, D.M., Douty, B.D., Baizman, E., Awad, M.M.A., Marceau, F., and Seoane, P.R. 1994. The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 91: 4693-4697.
12. Stewart, J.M., Gera, L., Hanson, W., Zuzack, J.S., Burkard, M., McCullough, R., and Whalley, E.T. 1996. A new generation of bradykinin antagonists. J. Immunopharmacol. 33: 51-60.
13. 2 in rats, dogs and monkeys. Life Sci. 47: 29-36.
14. Wirth, K., Hock, F.J., Albus, U., Linz, W., Alpermann, H.G., Anagnostopoulos, H., Henke, S., Breipohl, G., Konig, W., Knolle, J., and Scholkens, B.A. 1991. HOE140, a new potent and long acting bradykinin antagonist: in vivo studies. Br. J. Pharmacol. 102: 774-777.